ABSTRACT
Circulating tumor cells (CTCs) from peripheral blood have been detected in most epithelial malignancies. CTCs are very heterogeneous and can be captured via different technologies based on their physical and biological properties. The detection rates have varied depending on the technology used for enumeration. Detection, monitoring, and molecular analysis of CTCs provide a powerful and noninvasive approach for the detection of early disease, assessing prognosis and therapeutic response in cancer patients. Non-small cell lung cancer (NSCLC) is one of the most lethal malignancies in humans. Compared with other solid tumors, the number of CTCs in NSCLC is relatively low. Nevertheless, NSCLC is a particularly important disease for CTC evaluation for prognostic purposes because of the lack of a reliable protein-based tumor marker. Molecular analyses of CTCs have provided new insights into the biology of metastasis with important implications for the clinical management of cancer patients. We review current and emerging technologies for CTC detection, with a focus on enrichment and molecular analysis of CTCs, and their potential clinical applications in NSCLC.
INTRODUCTION
Lung cancer has become the leading cause of cancer-related deaths worldwide in recent years (1) . Metastasis is the most vital factor causing the adverse prognosis of cancer patients, not least in lung cancer, by compromising the function of an organ. 90% of cancer patients do not die because of their primary tumor; they are killed by metastatic disease (2) (3) (4) . Malignant cells localized within the primary tumour can invade through the basement membrane and migrate into circulation, finally travel to a distant tissue and establish a separate secondary tumour site in a new environment of a host organ, such as bone marrow, liver, lung or brain (5) (6) (7) . Unfortunately, the current high-resolution imaging technologies and serum tumor markers are incapable of detecting the early spread of tumor cells, the ongoing metastasis as early as possible, which prevented potentially effective early intervention. Ultrasensitive immunocytochemical and molecular assays have been recently developed to detect disseminated tumor cells (DTCs) in the bone marrow and circulating tumour cells (CTCs) in the peripheral blood of cancer patients. Application of DTCs analyses has provided new insight into the biology of metastasis with important implications for estimating prognosis and the clinical management of the patients with breast, colon, lung and prostate cancer (6, (8) (9) (10) (11) . Peripheral blood analyses, however, are more acceptable and convenient for patients with solid tumors than invasive bone marrow sampling which is the standard of care in patients with leukemia or lymphoma (10) . Enumeration of CTCs present in the peripheral blood of patients with malignant cancer could prove a useful tool for detection, characterization, prognosis and treatment monitoring (12) . CTCs occur at very low concentrations of one tumor cell in the background of millions of blood cells, in that only a few CTCs are contained per milliliter of peripheral blood (13, 14) . This presents a tremendous challenge for the development of a sensitive and specific detection method for CTCs, as well as for the clinical application. However, there have been major technological advances in recent years. CTCs can now be reliably identified in the peripheral bloodstream of cancer patients with metastatic disease, and their biological significance is being revealed. At least 13 other methods have been described to identify them by differences in biological and physical properties of CTCs (14) . The potential applications of CTC enumeration and characterization could facilitate several key areas of cancer therapeutics, such as guiding prognosis, measuring response to anticancer therapy, selecting patients for adjuvant chemotherapy, and detecting recurrent disease (14) (15) (16) . Only a few reports have been published on CTCs in nonsmall cell lung cancer (NSCLC) (17-22). When comparing data with the same technology, incidence of CTCs in NSCLC was lower compared with other tumors as reported by the CellSearch method(23). NSCLC is a particularly important disease for CTC evaluation for prognostic purposes because of the lack of a reliable protein based tumor marker(24). This review will discuss the most commonly methodology for detection of CTCs and their clinical utility with particular reference to NSCLC.
NON-SMALL CELL LUNG CANCER (NSCLC)
Lung cancer is a major health challenge worldwide, ranking at one of the most common malignancies in the world, and its incidence is rising in many countries. Lung Cancer is the most frequent cancer in terms of incidence (1.35 million new cases or 12.4% of the world total) and the deadliest cancer with more than 1.18 million deaths or 17.6% of the total (1, 25) . NSCLC accounts for the 80% of all lung cancers with a gloomy prognosis, and less than 15% of patients surviving beyond 5 years(26). NSCLC is divided into 3 types according to histological characteristics: squamous cell carcinoma (SCC; 25-30%), adenocarcinoma (AC; 32-40%), and large cell carcinoma (LCC; 8-16%). All of these subtypes are highly lethal and hard to distinguish clinically(27). Despite advances in surgery, chemotherapy, and radiotherapy over the last decades, the death rate from lung cancer has remained largely unchanged, which is mainly due to lack of effective diagnosis biomarker and occurrence of metastases in distant organs for the vast majority of lung cancer patients. In many cases, distant metastases have already developed by the time of the diagnosis of the primary lung lesions, and therefore the majority of patients requires systemic therapy (26, 28). Histological differentiation and staging of lung cancer is mandatory at time of diagnosis for the individual therapeutic stratification(29). In many patients, biopsies for the histopathological subtyping cannot be taken due to multimorbidity and instable clinical conditions of the patient or unfavorable localization of the tumor (26, 29). Meanwhile, unlike CEA in colorectal carcinoma and PSA in prostate cancer, tumor markers are not widely accepted in making treatment decisions for patients with lung cancer. At presentation, decisions in lung cancer treatment are based mainly on imaging rather than on fluid based biomarkers. Therefore, nearly 50% of earlystage NSCLC patients will relapse or develop distant metastases within 5 years even after potentially curative treatment as surgical removal of tumor mass(30). Early detection has consistently been shown as the best defense against any cancer, whereas the stage at diagnosis and the available options for curative surgery remain the most important prognostic factors. In lung cancer, for improvement of the survival of the patients with NSCLC, it is extremely important to establish feasible diagnostic methods of not only as accurate predictors for possible formation of metastasis but real-time monitoring of patient progress over the course of therapy.
CIRCULATING TUMOR CELLS (CTCS)
CTCs have attracted much interest in cancer research as a potential biomarker, as a guild for treatment decision making in cancer patients and as a means of studying the process of metastasis (31-33). The "seed and soil" hypothesis, which predicted the existent of CTCs in the peripheral blood of cancer patients, was firstly documented by Paget in 1889(34), which were also theorized by other nineteenth century physicians, with some even identifying the existence of malignant cells in the circulation of cancer patients(35). CTCs are defined as tumor cells disseminating from either primary sites or metastases, circulating freely in the peripheral blood of patients, at least some of which are ultimately capable of forming distant metastases, whereas extremely rare in the healthy people (6, 7, 36) . Highly aggressive CTCs may not only establish metastases in distant organs, but also be capable of self-seeding back to their original organs (37). The prognosis of carcinoma patients, even with small primary tumors, is mainly determined by the CTCs from the primary site to distant organs such as bone marrow, liver, lungs, or brain, and the subsequent outgrowth of these cells in their new microenvironment(35, 38). Despite of detection rates varied depending on the technology used for enumeration, it has now been shown that CTCs can be harvested from blood in various cancer subtypes, such as breast, colon, lung, and prostate cancers(39-42), which strongly suggested that CTC detection had huge potential of assisting malignancy diagnosis, estimating prognosis, monitoring disease recurrence, and response of the treatment (14, 36) . Moreover, characterization of CTCs offers new perspectives for researchers to renew our understanding of the evolution of tumour genomes during treatment and disease progression, and shed new light on the underlying mechanism of the biology of treatment resistance and metastasis. The detection of CTCs in peripheral blood of cancer patients holds great promise, and much of the research over the past few decades has been focused on the development of reliable methods for CTCs enrichment and identification (12, 13, 16) . It is known that even in patients with advanced cancers, CTCs exist in extreme rarity in patient blood, vastly outnumbered by normal blood cells (43-46). The identification of CTCs must be sensitive and specific enough to distinguish the malignant cells from all the other circulating non-tumor hematopoietic cells, which are usually combined with enrichment procedures. CTCs enrichment includes amounts of technologies based on the different properties of CTCs that distinguish them from the surrounding normal hematopoietic cells, including physical properties (size, density, electric charges, deformability) and biological properties (surface protein expression, viability, and invasion capacity) (13) . Techniques for physical properties, which based on the hypnosis that CTCs are often larger than normal leukocytes, include filtration of tumor cells by size through special microporous polycarbonate filters, such as the ISET (Isolation by Size of Epithelial Tumor Cells)(47, 48), density gradient centrifugation (Ficoll, OncoQuick)(49-51) or a novel threedimensional microfilter(52). Due to the lack of markers, these methods are generally considered not highly sensitive and poorly specific (53-55). Biological properties are mainly used in immunological procedures with antibodies against either tumor-associated antigens (positive selection) or the normal leukocyte antigen CD45 (negative selection) ( Figure 1 ). Until now, the most successful approaches have made use of the fact that epithelial cell commonly express the cell adhesion protein Epithelial cell adhesion molecule (EpCAM), which is absent in normal blood cells. The majority of studies have employed the CellSearchTM System (Veridex LLC, Huntingdon Valley, PA, USA) which is an immunomagnetic detection method employing magnetic beads coated with anti-EpCAM antibodies (13) . However, all EpCAM-based enrichment systems have the same limitation(56); EpCAM can be downregulated during epithelial-to-mesenchymal transition (EMT), which is a key developmental program that is often activated during cancer metastasis and invasion(57, 58). In addition, EpCAM is not necessarily expressed by all types of tumors(59, 60).
Other general limitation of CTCs detection is that there is no single marker that will reliably identify CTCs and be used independently for various types of tumors (14, 16, 35) . This limitation applies not only to different genetic characteristics among different tumor tissues, but also to different genetic characteristics in the same tumor tissue (61) (62) (63) . Meanwhile, tumor cells in circulation are heterogeneous. Some CTCs exist as individual cells, some as clusters of tumor cells, some associated with blood cells such as platelets and many non-viable cells (64) . Thus, the challenge for CTC research is thus not only to discriminate tumor cells circulating in the bloodstream from the huge majority of blood cells (14, 65) , but to identify the subpopulation of CTCs that are truly representative of the primary tumor and those that are capable of forming the lethal metastases that are (68, 69) . Longitudinal monitoring of CTCsderived genotypes may provide a noninvasive approach to identify drug-sensitivity and resistance-associated markers, guiding therapeutic decisions (70) . In addition to their potential use in directing the treatment, CTCs may also hold the key to monitoring for early dissemination of cancer(44, 50). However, the different assays, alternative definition criteria for CTCs, different, screened populations, limited number of patients, and different stages of the disease make the clinical significance of CTCs detection difficult to interpret. Therefore, the specificity and clinical utility of these methods still have to be demonstrated in large prospective multicenter studies to reach the high level for introduction into clinical practice.
CLINICAL APPLICATION OF CTCS IN NSCLC
Because peripheral blood samples can be obtained routinely and more readily, detection of CTCs may be a better tool to evaluate prognosis and rapidly assess therapeutic response. CTCs has been shown to correlate with poor progression free survival (PFS) and overall survival (OS) in breast, colorectal, and prostate cancers (41). When comparing data detected with the same technology, incidence of CTCs in NSCLC was lower compared with other tumors(23, 71). However, high definition CTC (HD-CTC) technology, a non-enrichment based method, is not only more sensitive in lung cancer, but adds an ability to examine multiparametric characteristics of CTCs such as nuclear size, CK expression, clustering and other cell categories etc. The HD-CTC assay applied in NSCLC identifies CTCs in 73% of all patients, including 85% of patients with early stage disease and 79% of patients with locally advanced disease, making this assay more promising in NSCLC (70) . Given the heterogeneity of NSCLC, no single marker gene was expressed in all NSCLC tumors and not in peripheral blood cells; therefore a multi-marker gene approach was employed. An assay, based on immunomagnetic bead enrichment followed by quantitative real-time PCR (QPCR) analyses of four selected marker genes, showed sufficient sensitivity and good specificity in discriminating CTCs in peripheral blood samples of advanced NSCLC patients from healthy controls(18).
Another study showed that the complementary dual technology approach of CTC analysis, a marker-dependent (CellSearch) and a marker-independent (ISET), allows more complete exploration of CTCs in patients with NSCLC(72).
Thus, the progress in CTCs technology development increased the potential applicability of technology for clinical utility of lung cancer patients. Most of the generally used techniques for CTCs detection have been investigated in lung cancer model with some successes in diagnosis, monitoring, and treatment decision making in patients with NSCLC. In patients with NSCLC, there is evidence that numeration of CTCs is prognostic and correlated with overall survival and stage of disease, and that CTCs counted before and during treatment mirror treatment response(31). Higher numbers of detected CTCs were associated with an unfavorable prognosis(20). The detection of EpCAM/MUC1 mRNA-positive CTCs before and after surgery is useful for predicting a poor prognosis in NSCLC patients who undergo curative surgery(22). A study by ISET, found that 30% of all samples who underwent surgery at all stages of NSCLC were identified to be positive for CTCs, while patients with high level of CTCs turned out to have a worse prognosis (73) . A propensity for increased CTC detection was observed as the disease progressed in individual patients (70) . In patients with primary lung cancer, the detection of CTCs in the blood was also found to be a useful surrogate marker of distant metastasis (74) Differential diagnosis of suspicious lung masses is essential for the selection of the appropriate therapy strategy. Increasingly, clinicians are relying on the genetic and molecular phenotype of certain cancers to guide treatment decisions. Some studies have investigated the molecular and genetic characterization of CTCs, beyond simple enumeration. CTCs offer promise as a surrogate for tissue where there is insufficient tissue for molecular analysis. With advances in technologies for examination of intact CTCs, personalized medicine with treatment selection according to molecular characteristics of CTCs was proposed. In patients with molecularly defined subtypes of NSCLC, CTCs demonstrate the same molecular changes as the cancer cells of the tumor (24, 61, 62) . Along with imaging and pathological diagnostic procedures, laboratory determinations of CTCs are essential for the histological differential diagnosis in lung cancer patients. A powerful example of the application of CTCs genotyping to personalized medicine lies in the detection of epidermal growth factor receptor (EGFR) mutations in patients with NSCLC(8), which is responsive to selective EGFR kinase inhibitors such as gefitinib and erlotinib (21, 75) . EGFR mutation analysis in lung cancer is now standard parts of diagnostic tests used by clinicians. Evidence of a correlation between decreases in CTCs counts and radiographic response in patients with advanced NSCLC was evaluated, which suggest a potential role for using CTCs decreases as an early indication of response to therapy (8, 21) . Correlation of low expression of ERCC1 on CTCs with longer PFS was observed in patients with metastatic NSCLC receiving platinum-based therapy (17). CTC counts are correlated with radiographic response and patient survival and to evaluate whether candidate predictive biomarkers can be assessed through molecular and cell-based assays on captured CTCs(21). In conclusion, progress in development of CTCs technology increased the potential applicability of CTCs detection in clinical utility for NSCLC patients to aid in both the earlier diagnosis and treatment management.
FUTURE DIRECTION
In contrast to tumor tissue or metastases, CTCs are easily obtained by venipuncture, thereby enabling repeated sampling over time. Nevertheless, due to the low number of these cells detectable with the currently available methods especially in patients with early-stage tumors, analysis of CTCs is still not part of routine tumor diagnostics in clinical practice. Given their rarity in the circulation, our knowledge of CTCs is heavily dependent on the technological approaches used for their detection and isolation. Most of studies on CTCs in NSCLC have some limitations, relatively small sample size and insufficiently the follow-up period. Therefore, the different technologies and also the differences among the screened populations make the clinical significance of CTCs detection difficult to interpret. In CTCs studies involving lung cancer, CTCs enumeration as a method to monitor patient progress has not been as convincing, because CTCs were not found in many study patients, and those patients with CTCs had numbers far lower than other cancer types. Improvements in CTCs capture efficiency, quantization, imaging, and molecular analyses would promote further clinical applications. In addition, we need to identify the most aggressive subset of CTCs that are the metastasisinitiating cells. Therefore, a prospective study with longterm follow-up in a large number of patients with NSCLC is required. Although extremely rare, CTCs based analysis enable us to study both quantitative and qualitative properties of the malignancy. Therefore, technological developments of sensitivity of CTCs detection may provide new opportunities for early diagnosis of metastasis, and unprecedented opportunity to develop therapeutic strategies to effectively treat and prevent NSCLC.
ACKNOWLEDGEMENT
Yi Han and Chongyu Su are the co-first authors.
REFERENCE
17. Das M, Riess JW, Frankel P, Schwartz E: ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. 
